Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kyowa Hakko Bio Co., Ltd. maintains a distributed prosecution profile within the Biotechnology & Pharmaceuticals sector. With 3 pending office actions currently active, the company is engaged in multiple simultaneous negotiations with the USPTO. This volume reflects an active phase of portfolio development across various technological sub-sectors.
The prosecution is notably decentralized, involving 3 distinct examiners and 3 distinct art units. This one-to-one ratio between pending actions and examiners suggests that no two active matters are being reviewed by the same individual or within the same specialized unit. Such a spread requires the company to adapt its legal arguments to the specific standards of three different administrative environments.
ARMATO JR, DENNIS IGNATIUS is the busiest examiner for the portfolio, though they are only responsible for 1 pending office action. This indicates that the workload is perfectly balanced across the examiner pool, with no single official exerting disproportionate influence over the company's pending claims. This distribution minimizes the risk associated with any single examiner's tendencies while requiring a broad strategy to manage the 3 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| §103 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549804 | COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT | OGUNBIYI, OLUWATOSIN A | 120d overdue |
| 18699491 | MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM | ARMATO JR, DENNIS IGNATIUS | 41d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549804 | COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT | OGUNBIYI, OLUWATOSIN A | 120d overdue |
| 16617497 | USE OF CITRULLINE AND GLUTATHIONE TO INCREASE MUSCLE MASS | DABKOWSKI, ERINNE R | 78d overdue |
| 18699491 | MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM | ARMATO JR, DENNIS IGNATIUS | 41d |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1645 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699491 | MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM | ARMATO JR, DENNIS IGNATIUS | 1651 | §101§102§112 | Non-Final OA | 41d | Pending | Apr 08, 2024 |
| 18549804 | COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT | OGUNBIYI, OLUWATOSIN A | 1645 | §101§102§112Other | Non-Final OA | 120d overdue | Pending | Sep 08, 2023 |
| 16617497 | USE OF CITRULLINE AND GLUTATHIONE TO INCREASE MUSCLE MASS | DABKOWSKI, ERINNE R | 1654 | §103 | Final Rejection | 78d overdue | Pending | Nov 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial